Testing the addition of a new immunotherapy drug, Atezolizumab (MPDL3280A), to the usual chemoradiation (CRT) therapy treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Greg Durm, MD
Primary Investigator
Overview
This study is being done to answer the following question: Can we lower the chance of small cell lung cancer growing or spreading by adding an immunotherapy drug (atezolizumab) to the usual treatment for this type of cancer?
Description
Participants will be randomly assigned to receive chemotherapy and radiation (called chemoradiation therapy or CRT) for up to 7 weeks, or to receive usual CRT for up to 7 weeks plus the study drug, atezolizumab, for up to one year.
All participants will be monitored for side effects during treatment. The doctor will follow up every 3 months for 2 years after treatment, every 6 months for the next 3 years, and annually after this 5 year period.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Limited Stage Small Cell Lung Cancer (LS-SCLC)
-
Age: Between 18 Years - 100 Years
-
Gender: All
Individuals at least 18 years of age with limited stage small cell lung cancer (LS-SCLC).
Individuals with surgical resection of small cell lung cancer, prior invasive malignancy, or evidence of metastatic disease will not be eligible.
Individuals with certain co-morbidities, or history of allogeneic organ transplant or immunodeficiency will not be eligible.
Women who are pregnant will not be eligible.
